Palisade Bio logo

Palisade BioNASDAQ: PALI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 March 2007

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$3.85 M
-99%vs. 3y high
11%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 15 Nov 2024 14:30:00 GMT
$2.52-$0.10(-3.82%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

PALI Latest News

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
globenewswire.com10 October 2024 Sentiment: POSITIVE

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA)

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com13 August 2024 Sentiment: POSITIVE

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

Palisade Bio Participates in Virtual Investor “What this Means” Segment
globenewswire.com31 July 2024 Sentiment: POSITIVE

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
globenewswire.com19 July 2024 Sentiment: POSITIVE

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC) PALI-1908 is in development to treat patients with active fibro stenotic Crohn's Disease (CD) Carlsbad, CA, July 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that European Patent Office (EPO) has issued a decision to grant notice for patent number 4,157,853 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” Based on the intention to grant notice, the Company expects the EPO to issue a patent July 31, 2024.

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
globenewswire.com11 July 2024 Sentiment: POSITIVE

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) before year end Carlsbad, CA, July 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of the first Good Manufacturing Practice (GMP) batch of its drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. The GMP manufacturing was conducted in partnership with Eurofins, a contract development and manufacturing organization.

Palisade Bio to Participate in the Virtual Investor Closing Bell Series
globenewswire.com24 June 2024 Sentiment: POSITIVE

Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET. As part of the event, J.D.

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
globenewswire.com21 June 2024 Sentiment: POSITIVE

– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics

Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now
zacks.com14 June 2024 Sentiment: POSITIVE

Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Palisade Bio to Present at the Virtual Investor Pitch Conference
globenewswire.com10 June 2024 Sentiment: POSITIVE

Live video webcast on Monday, June 17 th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00 PM ET. As part of the event, J.D.

Why Is Palisade Bio (PALI) Stock Up 57% Today?
InvestorPlace16 April 2024 Sentiment: POSITIVE

Palisade Bio stock is on the rise today following the release of more data for its ulcerative colitis treatment. The significant development is Palisade Bio finishing its evaluation of ex-vivo bioactivation of PALI-2108.

What type of business is Palisade Bio?

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

What sector is Palisade Bio in?

Palisade Bio is in the Healthcare sector

What industry is Palisade Bio in?

Palisade Bio is in the Biotechnology industry

What country is Palisade Bio from?

Palisade Bio is headquartered in United States

When did Palisade Bio go public?

Palisade Bio initial public offering (IPO) was on 30 March 2007

What is Palisade Bio website?

https://www.palisadebio.com

Is Palisade Bio in the S&P 500?

No, Palisade Bio is not included in the S&P 500 index

Is Palisade Bio in the NASDAQ 100?

No, Palisade Bio is not included in the NASDAQ 100 index

Is Palisade Bio in the Dow Jones?

No, Palisade Bio is not included in the Dow Jones index

When was Palisade Bio the previous earnings report?

No data

When does Palisade Bio earnings report?

Next earnings report date is not announced yet